Dr Nicola Fazio speaks about the different types of neuroendocrine tumours and the results of the Radiant-2 and Radiant 3 trials which were presented at ESMO 2010. Radiant 2 compared everolimus and octreotide long-acting release (LAR) with placebo and octreotide LAR in patients with advanced neuroendocrine tumours while the Radiant 3 trial compared everolimus with a placebo in patients with advanced pancreatic neuroendocrine tumours (pNET).Dr Fazio explains the mechanism of action of everolimus, the toxicities experienced by patients and discusses what conclusions can be made from the results of the Radiant trials.